Sunshine Biopharma, Inc. is focused on the research, development and commercialization of drugs designed to treat various forms of cancer. The Company’s lead compound, Adva-27a, is a multi-purpose anti-tumor compound currently in preclinical stage with plans to conduct Phase I clinical trials at the Segal Cancer Centre of the Jewish General Hospital, one of McGill University’s Hospital Centers located in Montreal, Canada.
Almost 1.5 million new cases of cancer are diagnosed in the U.S. each year, according to the American Cancer Society. Virtually all cancer types are either aggressive at the onset or become aggressive over time. There are two genes associated with aggressive forms of cancer: Her2 and Top2. Herceptin®, a drug marketed by Roche, is an effective treatment for Her2 positive patients, but there are currently no effective therapies that target Top2 positive patients. Management of Topoisomerase II (Top2) activity is vital in the fight against aggressive types of cancer, including multi-resistant breast cancer and metastatic cancer.
Adva-27a is a Carbon-Difluoride derivative of Etoposide, which has been on the market for more than twenty years under various brand names. Although Etoposide has enjoyed great success, it suffers from molecular instability leading to reduced efficacy and high toxicity. Using its Carbon-Difluoride platform technology, Advanomics constructed a derivative of Etoposide that is up to 16-times more effective at killing multi-drug resistant breast cancer cells than the existing Etoposide molecule. This new compound can be taken orally, and if FDA approved, will be the only Top2 Inhibitor on the market.
The U.S. Food and Drug Administration’s (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma’s lead compound could significantly exceed the typical revenues generated from anti-cancer drugs, which in general reach $1 billion in annual sales within two or three years of FDA approval.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment